10-Q: Palatin Technologies Swings to Profit on Boehringer Ingelheim Deal

Palatin Technologies reported a significant shift to net income in Q1 2026, driven by a new collaboration and license agreement with Boehringer Ingelheim, while also regaining its NYSE American listing.

Summary

• Palatin Technologies, Inc. reported net income of $4,677,534 for the three months ended September 30, 2025, a substantial improvement from a net loss of $7,823,649 in the prior year period.
• Collaboration and license revenue surged to $8,847,550 for the quarter, up from $0 in the same period last year, primarily due to the Boehringer Ingelheim agreement.
• Research and development expenses decreased significantly to $2,525,766 from $5,743,754 year-over-year, mainly due to reduced spending on MCR programs.
• Selling, general and administrative expenses also decreased to $1,660,731 from $2,020,931, primarily due to lower compensation costs.
• The company's total stockholders' equity shifted from a deficiency of $(4,777,045) as of June 30, 2025, to a positive equity of $396,399 as of September 30, 2025.
• Cash and cash equivalents stood at $1,273,083 as of September 30, 2025, down from $2,564,265 as of June 30, 2025.
• Management concluded that prior conditions raising substantial doubt about the company's ability to continue as a going concern no longer exist, citing $5.4 million received in October 2025 from Boehringer Ingelheim and $16.9 million net proceeds from a November 2025 public offering.
• The company's common stock was reinstated for trading on the NYSE American under the symbol PTN, effective November 12, 2025, after being suspended and traded on OTCQB.
• A 1-for-50 reverse stock split was made effective on August 11, 2025.

Sentiment

Score: 8

Explanation: The company demonstrated a strong financial turnaround with a significant net income driven by a major collaboration agreement. The successful pipeline advancements and regaining NYSE listing are substantial positives. While liquidity remains a long-term challenge requiring further funding, recent capital raises and the positive going concern assessment mitigate immediate concerns. The legal proceeding is a minor negative, but overall, the quarter shows strong progress.

Positives

• Achieved net income of $4,677,534 for the quarter, a significant turnaround from a net loss in the prior year.
• Secured a major Research Collaboration, License and Patent Assignment Agreement with Boehringer Ingelheim, generating $8,847,550 in collaboration and license revenue.
• The Boehringer Ingelheim agreement includes potential for up to $21.2 million in near-term research milestones and up to $307 million in success-based development, regulatory, and commercial milestones, plus tiered royalties.
• Successfully completed a Phase 3 clinical trial for PL9643 (dry eye disease) and reported positive topline data for bremelanotide with tirzepatide (obesity) and PL8177 (ulcerative colitis).
• Regained compliance with NYSE American listing standards and recommenced trading on NYSE American under PTN.
• Management has concluded that the prior conditions raising substantial doubt about the company's ability to continue as a going concern no longer exist, supported by recent capital raises totaling approximately $22.3 million post-quarter end.

Negatives

• Cash and cash equivalents decreased to $1,273,083 as of September 30, 2025, from $2,564,265 as of June 30, 2025.
• Current liabilities increased slightly to $8,218,261 as of September 30, 2025, from $8,010,030 as of June 30, 2025.
• The company has incurred operating losses and negative cash flows from operations since inception and anticipates incurring significant future expenses, requiring substantial additional financing or revenues.
• Concentration of credit risk exists with cash and cash equivalents primarily invested in one account and revenue/accounts receivable generated by one customer (Boehringer Ingelheim).

Risks

• Ability to obtain additional financing on acceptable terms or at all, including unavailability of funds or delays due to economic disruptions.
• Expectation to incur losses for the foreseeable future and may never achieve or maintain profitability.
• Business, financial condition, and results of operations may be adversely affected by increases in costs and delays in human clinical trials, performance of contractors/suppliers, supply chain constraints, and labor shortages.
• Uncertainty regarding Boehringer Ingelheim's ability to successfully develop a product for retinal diseases.
• Uncertainty regarding Cosette Pharmaceuticals' sales of Vyleesi to generate significant milestone payments.
• Risks associated with the results and timing of clinical trials and regulatory submissions for late-stage products.
• Difficulty in estimating the costs and timing of future Phase 1, Phase 2, and Phase 3 clinical trials for any product under development.
• Impact of fluctuations in foreign exchange rates.
• Impact of geopolitical instability, economic uncertainty, financial markets volatility, or capital markets disruption (e.g., Russia-Ukraine conflict, Middle East conflicts).
• Impact of legislative or regulatory healthcare reforms in the United States.
• Ability to adapt to changes in global economic conditions and competing products/technologies.
• Inadequate funding for the FDA, SEC, and other U.S. government agencies leading to government shutdowns or other disruptions, which could prevent timely product development, regulatory review, and access to capital markets.

Future Outlook

Management expects existing cash and cash equivalents, supplemented by recent capital raises, to be sufficient to fund operations through the next twelve months following the issuance of the financial statements. The company will need additional funding to complete required clinical trials and regulatory applications. Key pipeline milestones include an IND filing for a novel once-weekly MC4R peptide agonist for obesity in Q1 2026, an IND filing for PL7737 (oral small molecule MC4R agonist) in Q1 2026, and a second Phase 3 clinical trial for PL9643 (dry eye disease) targeted for H1 2026.

Management Comments

• Management intends to utilize existing capital resources for general corporate purposes and working capital, including clinical development of the MC1R and MC4R programs, and development of other portfolio products.
• Management has concluded that the prior conditions and events raising substantial doubt about the company's ability to continue as a going concern no longer exist as of the date these financial statements are issued.

Industry Context

Palatin Technologies operates in the highly competitive biopharmaceutical industry, focusing on melanocortin receptor system modulation for various therapeutic areas. The collaboration with Boehringer Ingelheim for retinal diseases highlights a trend of larger pharmaceutical companies partnering with specialized biotech firms for novel drug candidates. The company's pipeline, including obesity and dry eye disease treatments, addresses significant unmet medical needs and aligns with active areas of research and development in the broader pharmaceutical landscape. The successful Phase 3 for PL9643 and positive Phase 2 data for obesity and ulcerative colitis candidates position Palatin within competitive therapeutic markets, where strategic partnerships are crucial for advancing products through costly development and commercialization stages.

Comparison to Industry Standards

• The significant increase in collaboration revenue from Boehringer Ingelheim is a positive indicator, aligning with industry trends where early-stage biotechs leverage partnerships to de-risk development and secure funding. While specific comparable deals are not detailed in the filing, the potential for up to $307 million in milestones and tiered royalties suggests a substantial valuation for the licensed technology, comparable to other early-to-mid-stage licensing agreements in the ophthalmology and metabolic disease sectors.
• The reduction in R&D expenses, while contributing to profitability, could be viewed with caution if it signals a slowdown in internal development efforts not offset by partner-funded programs. Successful Phase 3 completion for PL9643 and positive Phase 2 data for obesity and ulcerative colitis candidates are critical milestones that, if replicated by larger industry players, would typically command significant market attention and potential for further partnerships or acquisitions, similar to recent deals involving companies like Viking Therapeutics or Madrigal Pharmaceuticals in metabolic diseases, or various ophthalmology-focused biotechs.

Corporate Governance

Legal Proceedings

• H.C. Wainwright & Co., LLC (Wainwright) v. Palatin Technologies, Inc. (Case No: 650878/2025): Filed February 13, 2025, in the Supreme Court of the State of New York, County of New York. Wainwright asserts three causes of action for breach of contract, seeking monetary damages and warrants allegedly due under a January 29, 2024 engagement agreement. Palatin denies liability and plans to vigorously defend. Management believes a loss is reasonably possible but not probable and is unable to estimate the potential loss.

Related Party Transactions

• June 2025 Private Placement: Carl Spana (President and CEO), Stephen T. Wills (EVP, CFO, COO), John K.A. Prendergast (Director and Chairperson), and Alan W. Dunton (Director) purchased an aggregate of 3,400 shares of Series D Convertible Preferred Stock and Series I common stock purchase warrants, totaling $340,000 gross proceeds.

Stakeholder Impact

• Shareholders: Positive impact from the shift to net income, significant collaboration revenue, regaining NYSE listing, and the conclusion that going concern doubt no longer exists. However, dilution from recent capital raises and the ongoing legal proceeding could be concerns.
• Employees: Continued employment and potential for growth with ongoing research programs and strategic partnerships. Stock-based compensation remains a component of remuneration.
• Customers/Partners (Boehringer Ingelheim, Cosette): Boehringer Ingelheim is a key partner, providing significant revenue and funding for retinal disease research. Cosette continues to market Vyleesi, with potential for future milestone payments to Palatin.
• Creditors: Improved financial position and liquidity outlook reduce immediate credit risk, although the company still has substantial liabilities and requires future funding.

Next Steps

• Boehringer Ingelheim to continue research, development, and commercialization of melanocortin receptor-targeted peptides for retinal diseases.
• Palatin to conduct research services for Boehringer Ingelheim for a two-year period (extendable).
• Actively engage in discussions with potential partners and licensees for PL9643 (dry eye disease) to progress through development, approval, and commercialization.
• IND filing projected in Q1 2026 for a novel once-weekly MC4R peptide agonist for obesity indications.
• IND filing projected in Q1 2026 for PL7737, an oral small molecule MC4R agonist.
• Second Phase 3 clinical trial targeted for the first half of calendar year 2026 for PL9643 (dry eye disease).
• Continue to vigorously defend against the H.C. Wainwright & Co., LLC lawsuit, which will proceed to the discovery stage if no resolution is reached.

Key Dates

Recommendation

Palatin Technologies has demonstrated a strong financial turnaround with a significant net income and substantial collaboration revenue from Boehringer Ingelheim, which is a major positive development. The successful reinstatement of its NYSE American listing and management's positive assessment of its going concern status, bolstered by recent capital raises, provide a more stable outlook. However, the company still operates with a history of losses, a relatively low cash balance (pre-November offering), and a reliance on future funding for its extensive pipeline. The ongoing legal dispute with H.C. Wainwright & Co. adds a layer of uncertainty. While the recent positive developments are encouraging, the long-term profitability and successful commercialization of its pipeline remain contingent on further clinical success and strategic partnerships. A 'hold' recommendation reflects the improved financial health and strategic progress, balanced against the inherent risks and capital requirements of a clinical-stage biopharmaceutical company.

Keywords

Palatin Technologies, PTN, Biopharmaceutical, Melanocortin Receptor, MC4R agonist, MC1R agonist, Obesity, Diabetic Retinopathy, Dry Eye Disease, Ulcerative Colitis, Boehringer Ingelheim, Clinical Trials, SEC Filing, 10-Q, Financial Results, Biotech, Drug Development, Licensing Agreement, Warrants, Capital Raise, NYSE American